The Relapsing Remitting Multiple Sclerosis (RRMS) drugs in development market research report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Relapsing Remitting Multiple Sclerosis (RRMS). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued products.

GlobalData tracks 54 drugs in development for Relapsing Remitting Multiple Sclerosis (RRMS) by 49 companies/universities/institutes. The top development phase for Relapsing Remitting Multiple Sclerosis (RRMS) is phase ii with 26 drugs in that stage. The Relapsing Remitting Multiple Sclerosis (RRMS) pipeline has 53 drugs in development by companies and one by universities/ institutes. Some of the companies in the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline products market are: Sanofi, Biogen and Cinnagen.

The key targets in the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline products market include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2), Cells Expressing B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), and B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1).

The key mechanisms of action in the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline product include Tyrosine Protein Kinase BTK (Bruton Tyrosine Kinase or B Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or BTK or EC 2.7.10.2) Inhibitor with four drugs in Phase III. The Relapsing Remitting Multiple Sclerosis (RRMS) pipeline products include 12 routes of administration with the top ROA being Intravenous and nine key molecule types in the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline products market including Small Molecule, and Monoclonal Antibody.

Relapsing Remitting Multiple Sclerosis (RRMS) overview

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS), a chronic autoimmune condition that affects the central nervous system. In RRMS, individuals experience intermittent episodes of new or worsening symptoms (relapses or exacerbations) lasting days to weeks, followed by periods of partial or complete recovery (remission) with stable or improved function. Symptoms of RRMS can vary widely and may include fatigue, numbness or tingling, muscle weakness, vision problems, balance and coordination difficulties, cognitive changes, and problems with bladder or bowel function. The severity and specific symptoms can differ among individuals and can also vary over time. During the early stages of RRMS, most individuals experience relapses followed by remissions. Over time, some people may transition to a secondary progressive form of MS, where disability accumulates steadily, with or without relapses. The exact cause of RRMS is not fully understood, but it is believed to involve a complex interaction between genetic, environmental, and immunological factors. In MS, the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers in the brain and spinal cord, leading to nerve damage and disruption of nerve signals.

For a complete picture of Relapsing Remitting Multiple Sclerosis (RRMS)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.